Top in cardiology: ‘Quadpill’ strategy for BP, myocardial injury in COVID-19

Healio provided coverage of the European Society of Cardiology. Highlights from the meeting led the top stories in cardiology last week.

One presentation focused on the use of a “quadpill” strategy for lowering BP. Another evaluated the prognostic role of myocardial injury in COVID-19 and the underlying mechanisms of injury.

Read these a more top stories in cardiology below:

‘Quadpill’ strategy effective, safe, tolerable vs. monotherapy for BP lowering

Use of a “quadpill” capsule containing quarter doses of four antihypertensive medications conferred greater BP reductions compared with monotherapy, with similar safety and tolerability, a speaker reported. Read more.

Myocardial injury common, but mortality risk not higher with concomitant COVID-19 diagnosis

In a new study, myocardial injury was common among patients with suspected COVID-19, but the risk for death from myocardial injury was not higher with a positive COVID-19 diagnosis. Read more.

Flu vaccine soon after heart attack cuts death, CV risk

Influenza vaccination early after myocardial infarction or in high-risk coronary artery disease was associated with a 28% lower risk for all-cause death, myocardial infarction or stent thrombosis at 12 months compared with placebo, according to results of the IAMI trial. Read more.

Aggressive BP lowering reduces CV events in older adults with hypertension

Intensive treatment to a systolic BP target of 110 mm Hg to less than 130 mm Hg was associated with a 26% reduced risk for cardiovascular events in older adults with hypertension compared with standard BP management. Read more.

CV safety of prostate cancer therapies ‘remains unresolved’: PRONOUNCE

In the PRONOUNCE trial, which aimed to compare the cardiovascular safety of androgen deprivation therapies for prostate cancer, there was no difference in major adverse cardiovascular events at 1 year among adults with prostate cancer and atherosclerotic CVD. Read more.